GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo

Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers

The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2

India reiterates commitment to adolescents on launch of ‘Economic Case for Investment in the Well-being of Adolescents in India’ report

Report highlights significant improvements in adolescent well-being in India

Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan

The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed

GlaxoSmithKline Pharmaceuticals appoints GoApptiv as super stockist

This tie-up will have no impact on any other brands of the company

Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Association 2024 Congress

DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia

Investing in Malaysia's largest clinic operator to expand the healthcare business

Sumitomo Pharma announces availability of ORGOVYX in Canada

The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer